跳至主要内容
临床试验/NCT04222647
NCT04222647已完成2 期

Prospective, Open-label, Monocenter, Trial to Investigate the Efficacy and Tolerability of WO533, a Lactic Acid Containing Vaginal Suppository, in a Panel of Post-menopausal Women Suffering From Vulvovaginal Atrophy (VVA)

Dr. August Wolff GmbH & Co. KG Arzneimittel1 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2020年1月27日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
43
试验地点
1
主要终点
VMI

研究概览

简要总结

The aim of the study is to investigate the efficacy and tolerability of a lactic acid containing vaginal suppository with respect to the application in post-menopausal women with VVA.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Post-menopausal women with subjective symptomatology of vulvovaginal atrophy
  • Signed written informed consent before participation in the trial

排除标准

  • Known hypersensitivity against any of the ingredients of the investigational product
  • Systemic hormonal replacement therapy, or phytohormonal therapy or use of SERMs within 3 months before and / or during the conduct of the trial
  • Local hormonal therapy (vagina/vulva) within 3 months before the trial
  • If in the opinion of the investigator the patient should not participate in the study for any reason

研究组 & 干预措施

WO533

Experimental

Formulation containing WO533 for intravaginal application

干预措施: WO533 (Drug)

结局指标

主要结局

VMI

时间窗: Day 1 to 43

Change of the Vaginal Maturation Index (VMI)

次要结局

  • Vaginal pH(Day 1 to 8, day 8 to 43, and day 1 to 43)
  • Subjective vulvovaginal atrophy symptoms(Day 1 to 8, day 8 to 43, and day 1 to 43)
  • Global judgment of the tolerability by the Investigator(Day 1 to 43)
  • Global judgment of the tolerability by the patient(Day 1 to 43)
  • Adverse events(Day 1 to 43)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验